CRDF Cardiff Oncology1.95-0.99 (-33.7%)
Premarket Decliner
CRDF Cardiff Oncology2.94+0.04+1.4%
Premarket:2.24-0.70 (-23.8%)
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Globe NewswireTue, 27-Jan 7:05 AM
CRDF Cardiff Oncology3.23+0.05 (+1.6%)
CRDF Cardiff Oncology2.90-0.02 (-0.7%)
CRDF Cardiff Oncology2.36+0.07 (+3.1%)
CRDF Cardiff Oncology2.21+0.02 (+0.9%)